US Stock Insider Trading | Apogee Therapeutics disclosed 9 insider transactions on February 4

2026-02-19 03:01:20

On February 4, 2026, Apogee Therapeutics (APGE) disclosed nine insider transactions. Executive Dambkowski Carl purchased 4,125 shares on February 4, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 4, 2026	Executive	Dambkowski Carl	February 4, 2026	Sell	1,420	65.83	$93,500
February 4, 2026	Executive	Dambkowski Carl	February 4, 2026	Sell	100	67.88	$6,788.00
February 4, 2026	Executive	Dambkowski Carl	February 4, 2026	Buy	4,125	22.86	$94,300
February 4, 2026	Executive	Dambkowski Carl	February 4, 2026	Sell	2,481	64.88	$161,000
February 4, 2026	Executive	Henderson Jane	February 2, 2026	Sell	792	65.21	$51,600
February 4, 2026	Executive	Dambkowski Carl	February 4, 2026	Sell	1,299	66.85	$86,800
February 4, 2026	Executive	Henderson Jane	February 2, 2026	Sell	1,108	66.15	$73,300
February 4, 2026	Executive	Henderson Jane	February 2, 2026	Sell	100	66.89	$6,689
February 4, 2026	Executive	Dambkowski Carl	February 4, 2026	Sell	200	68.94	$13,800
January 22, 2026	Director	Fairmount Funds Management LLC	January 22, 2026	Sell	1.75 million	76.30	$134 million

[Company Information]

Apogee Therapeutics, Inc. was incorporated in Delaware on June 9, 2023. Related to this offering, as a holding company, it will own 100% of Apogee Therapeutics, LLC, and indirectly own its subsidiaries. The company is a biotechnology firm dedicated to developing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and related inflammatory and immunological conditions, which are unmet medical needs. The company’s antibody programs aim to overcome limitations of existing therapies by targeting mature mechanisms of action and utilizing advanced antibody engineering to optimize half-life.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes